Die Aktie kennt nur eine Richtung ..... seit Tagen wird die Aktie in Canada aufgekauft. Ein neues Hoch folgt dem nächsten. Man erwartet eine Übernahme durch Cardiome.
Medicure Inc (V.MPH) Sector: Healthcare | Sub-Sector: Biotechnology Primary Symbol: V.MPH.H Alternate Symbol(s): MCUJD|MCUJ|MCUJF Medicure, Inc., is a biopharmaceutical company. It is engaged in the research, development and commercialization of human therapeutics.
Medicure Aktien signifikant unterbewertet. Kursziel $ 2,80 Medicure! Der Chart spricht für einen sehr bullishen Trend Ausbruch der Aktie steht unmittelbar bevor. Medicure Aktien vor einer starke Rallye. Vergleichen Sie den Chart von Medicure und Cardiome. Medicure eine historische Chance auf eine deutliche Performance.
MEDICURE ENGAGES KNIGHT THERAPEUTICS INC. TO PROVIDE ADVISORY SERVICES
Medicure Inc. has entered into an arrangement with Knight Therapeutics Inc. under which Knight will provide advisory services to help advance Medicure's United States specialty pharmaceutical business and corporate development initiatives.
"Medicure is pleased to have the opportunity to work with Jonathan Ross Goodman, co-founder of Paladin Labs Inc. and chief executive officer of Knight Therapeutics Inc." stated Dr. Albert D. Friesen, chief executive officer and chair of Medicure. "We look forward to benefiting from the depth of experience and networks that he has built up in establishing and growing a successful specialty pharmaceutical business."
Jonathan Ross Goodman, chief executive officer of Knight Therapeutics, commented, "I am pleased to leverage my skills and experience to help Medicure further grow its business."
Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE:MPH)(OTCQB:MCUJF), a specialty pharmaceutical company, reports that, in view of the recent market activity in the Company's stock, the Investment Industry Regulatory Organization of Canada ("IIROC") has contacted the Company in accordance with its usual practice.
Although the Company ordinarily does not comment on market activity or market speculation, the Company is aware of the increased market activity in its common stock subsequent to our most recent press releases, including the announcement of March 26, 2014 relating to the financial results from the third quarter fiscal 2014 and the announcement of April 14, 2014 relating to the Company's advisory services agreement with Knight Therapeutics Inc.
Over the past several years the Company has been exploring opportunities to grow its business through acquisition. The Company is currently pursuing one specific opportunity, under which the Company would be a party to an acquisition. There is no assurance that this potential transaction, or any other transaction, is going to be completed.
The transaction contemplated is subject to, among other things, the negotiation and execution of a definitive binding agreements and other documentation, approval of the board of directors of the Company and that of the other parties to the transaction, and the completion of remaining due diligence activities. There can be no assurance that these conditions precedent, or any other conditions precedent, will be satisfied.
About Medicure Inc.
Medicure is a specialty pharmaceutical company focused on the development and commercialization of novel small molecule therapeutics. The primary focus of the Company and its subsidiaries is the marketing and distribution of AGGRASTAT (tirofiban HCl) for non-ST elevation acute coronary syndrome in the United States, where it is sold through the Company's U.S. subsidiary, Medicure Pharma, Inc. For more information on Medicure please visit www.medicure.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward Looking Information Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes", "may", "plans", "will", "estimates", "continues", "anticipates", "intends", "expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-looking statements, including the potential for any growth through acquisition, are based on the current assumptions, estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking statements.
Such risk factors include, among others, the Company's future product revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company's research and development projects; the availability of financing for the Company's commercial operations and/or research and development projects, or the availability of financing on reasonable terms; results of current and future clinical trials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings with the applicable Canadian securities regulatory authorities or the US Securities and Exchange Commission, and in the "Risk Factors" section of its Form 20F for the year ended May 31, 2013.
Contacts: Medicure Inc. Dawson Reimer President & COO 888-435-2220 204-488-9823 (FAX) email@example.com www.medicure.com